综合医院门诊抑郁障碍和焦虑障碍患者处方变化分析

黄文武; 费爱丽; 沈禹泽; 徐磊; 林铮<sup>*</sup>

引用本文:	黄文武,费爱丽,沈禹泽,徐磊,林铮.综合医院门诊抑郁障碍和焦虑障碍患者处方变化分析[J].中国现代应用药学,2016,33(9):1205-1208.
	HUANG Wenwu,FEI Aili,SHEN Yuze,XU Lei,LIN Zheng.Trend and Change of Antipsychotic Prescriptions of Anxiety Disorders and Depressive Disorders in Out-patient Clinic[J].Chin J Mod Appl Pharm(中国现代应用药学),2016,33(9):1205-1208.

【打印本页】【HTML】【下载PDF全文】【查看/发表评论】【EndNote】【RefMan】【BibTex】

←前一篇|后一篇→

过刊浏览高级检索

本文已被：浏览 2922次下载 1789次	码上扫一扫！
分享到：微信更多字体:加大+\|默认\|缩小-
综合医院门诊抑郁障碍和焦虑障碍患者处方变化分析
黄文武¹, 费爱丽², 沈禹泽³, 徐磊⁴, 林铮⁴
1.温州医科大学附属康宁医院，浙江温州 325007;2.嘉兴市第二医院，浙江嘉兴 314000;3.杭州市余杭区第一医院，杭州 311100;4.浙江大学医学院附属第二医院，杭州 310009

摘要:

目的调查某大型三甲综合医院门诊抑郁障碍和焦虑障碍的处方5年前后变化情况，分析临床药物治疗演变规律。方法以2010年及2015年全年作为2个调查时段，根据相关诊断导出相对应的处方，分析比较其中的精神类药物的使用情况。结果 2015年抑郁障碍和焦虑障碍门诊治疗上使用占比高的药物分别为选择性5-HT再摄取抑制剂(SSRI，27%)、第二代抗精神病药(SGA，19.9%)、苯二氮卓类(BDZ，18.5%)及选择性5-HT/NE再摄取抑制剂(SNRI，15.5%)，单药治疗中SSRI(51.7%)及SNRI(40%)占有相当大的比例，联合治疗中占比高的为SSRI(31.8%)、SGA(26%)及SNRI(17.4%)；2015年较2010年相比，β受体阻断剂及三环类占比明显下降，联用药物数量较之前明显减少，从3药联合变为以双药联合治疗为主。结论综合医院抑郁障碍和焦虑障碍门诊治疗药物选择较5年前更加规范和个体化；选择疗效良好、不良反应轻微的药物及联合用药已成为主要趋势。

关键词: 焦虑障碍抑郁障碍选择性5-HT再摄取抑制剂选择性5-HT/NE再摄取抑制剂

DOI：

分类号:

基金项目:浙江省中医药科技计划(2014ZA067)；浙江省卫生厅科技计划(2014KYA100)；浙江省教育厅项目(Y201432522)

Trend and Change of Antipsychotic Prescriptions of Anxiety Disorders and Depressive Disorders in Out-patient Clinic

HUANG Wenwu¹, FEI Aili², SHEN Yuze³, XU Lei⁴, LIN Zheng⁴

1.Kangning Hospital Affiliated Wenzhou Medical University, Wenzhou 325000, China;2.The Second Hospital of Jiaxing, Jiaxing 314000, China;3.The First People’s Hospital of Yuhang District of Hangzhou City, Hangzhou 311100, China;4.The Second Affiliated Hospital of Zhejiang University College of Medicine, Hangzhou 310009, China

Abstract:

OBJECTIVE To investigate the changes of anti-anxiety and anti-depression prescriptions in a large general hospital over the 5 years and to find the trend of drug therapy. METHODS reviewed the prescriptions of anxiety and depression disorder patients in outpatient, respectively in 2010 and 2015, and analyzed the proportion of medication. RESULTS In 2015, the most medication for anxiety and depression disorder were SSRI, SGA, BDZ, SNRI. The most of proportion were SSRI and SNRI in monotherapy, and SSRI, SNRI and SGA in combined treatment. The large changes between 2015 and 2010 were that proportions of β-blockers and TCAs were dropping dramatically and the combined treatment with 3 drugs was replaced by 2 drugs in the majority medication. CONCLUSION Medication for anxiety and depression disorder in the general hospital tends to choice the higher efficacy and mildly side-effect drugs and combined treatment.

Key words: anxiety disorders depressive disorder SSRI SNRI